第二代抗精神病藥物市場依適應症、藥物類別、給藥途徑、通路和地區分類

Second Generation Antipsychotics Market, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2025年05月05日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年全球第二代抗精神病藥物市場規模為 102.5 億美元，到 2032 年將達到 156.7 億美元，2025 年至 2032 年的複合年成長率為 6.25%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	102.5億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	6.25%	2032年價值預測	156.7億美元

近年來，由於精神疾病盛行率的上升和對有效治療的需求的增加，全球第二代抗精神病藥物市場出現了顯著成長。第二代抗精神病藥，也稱為非典型抗精神病藥，已成為治療各種精神疾病的首選藥物，包括思覺失調症、躁鬱症和重度憂鬱症。與第一代抗精神病藥物相比，這些藥物具有多種優勢，包括療效提高、錐體外系副作用減少和耐受性更好。受人們精神健康意識增強、新型製劑開發和適應症擴大的推動，第二代抗精神病藥物市場預計將保持擴張趨勢。

市場動態：

全球第二代抗精神病藥物市場受到多種因素驅動，包括老年人口的成長和人們對精神健康意識的不斷提高。根據世界衛生組織 (WHO) 估計，全球約有 4.5 億人患有精神疾病，對有效治療的需求龐大。此外，第二代抗精神病藥物長效注射劑型的開發提高了患者的依從性和便利性，進一步促進了市場成長。然而，市場限制因素包括這些藥物成本高、可能產生的副作用以及與精神疾病相關的恥辱感。關鍵藥物專利到期和學名藥的出現也可能影響市場動態。儘管如此，由於對個人化機會的日益關注、新型藥物輸送系統的市場開發以及第二代抗精神病藥物在其他精神疾病治療中的應用不斷擴大，市場仍然存在巨大的成長機會。

本研究的主要特點

本報告對全球第二代抗精神病藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球第二代抗精神病藥物市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
全球第二代抗精神病藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球第二代抗精神病藥物市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 10.25 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.25%	2032 Value Projection:	USD 15.67 Bn

The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:

This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global second generation antipsychotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- Autism Spectrum Disorder
- Other Indications
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Asenapine
- Clozapine
- Paliperidone
- Brexpiprazole
- Lurasidone
- Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Johnson & Johnson
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Otsuka Pharmaceutical
- Lundbeck
- Sanofi
- Merck & Co.
- AbbVie
- Takeda Pharmaceutical
- Amgen
- GlaxoSmithKline
- Alkermes

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Second Generation Antipsychotics Market, By Indication
- Global Second Generation Antipsychotics Market, By Drug Class
- Global Second Generation Antipsychotics Market, By Route of Administration
- Global Second Generation Antipsychotics Market, By Distribution Channel
- Global Second Generation Antipsychotics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Second Generation Antipsychotics Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Schizophrenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Second Generation Antipsychotics Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Quetiapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Olanzapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Asenapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clozapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Paliperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Brexpiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lurasidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Second Generation Antipsychotics Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Second Generation Antipsychotics Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Second Generation Antipsychotics Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alkermes
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies